2,5-二甲氧基-N-3-喹啉-苯磺酰胺 | 496014-13-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2,5-二甲氧基-N-3-喹啉-苯磺酰胺
• 英文名称: 2,5-dimethoxy-N-(quinolin-3-yl)benzenesulfonamide
• 英文别名: MLS-0038949；DQB；2,5-dimethoxy-N-quinolin-3-ylbenzenesulfonamide
• CAS: 496014-13-2
• 化学式: C₁₇H₁₆N₂O₄S
• 分子量: 344.391
• InChiKey: JZSPHTPWUXNQGB-UHFFFAOYSA-N

物化性质

• 沸点：
  564.1±60.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  85.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-氨基喹啉 、 2,5-二甲氧基苯磺酰氯 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2,5-二甲氧基-N-3-喹啉-苯磺酰胺
  参考文献：
  名称：

  Self-assembling peptide–etoposide nanofibers for overcoming multidrug resistance

  摘要：

  Nap-GFFpYK-etoposide1/2（NFE1/2）增加依托泊苷的水溶性，加快其细胞摄取速度，并保护依托泊苷免受MDR介导的外流，从而显著提高抗癌疗效。

  DOI：

  10.1039/d0cc06387h

文献信息

• [EN] QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE QUINOLÉINE ET DE QUINAZOLINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：STINGRAY THERAPEUTICS INC

  公开号：WO2020190912A1

  公开（公告）日：2020-09-24

  Compounds and methods for their preparation and use as therapeutic or prophylactic agents, fo example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1).

  化合物及其制备和用作治疗或预防剂的方法，例如通过靶向Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1)来治疗癌症、细菌或病毒性疾病。
• Self-assembling peptide–etoposide nanofibers for overcoming multidrug resistance
  作者：Li-Song Zhang、Li-Xin Yan、Shan Gao、Hui Long、Zhen Xi、Lu-Yuan Li、Zhi-Song Zhang

  DOI：10.1039/d0cc06387h

  日期：——

  Nap-GFFpYK-etoposide1/2 (NFE1/2) increase the water solubility of etoposide, speed up its cellular uptake and protect the etoposide from MDR-mediated efflux, thus significantly improving the anticancer efficacy.

  Nap-GFFpYK-etoposide1/2（NFE1/2）增加依托泊苷的水溶性，加快其细胞摄取速度，并保护依托泊苷免受MDR介导的外流，从而显著提高抗癌疗效。
• Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
  申请人：Burnham Institute for Medical Research

  公开号：EP2433496A1

  公开（公告）日：2012-03-28

  Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.

  本文公开的化合物是组织非特异性碱性磷酸酶抑制剂。所公开的化合物可用于治疗、预防或减轻血管钙化、动脉钙化和其他心血管疾病。
• Quinoline and quinazoline compounds and methods of use thereof
  申请人：Stingray Therapeutics, Inc.

  公开号：US11407729B2

  公开（公告）日：2022-08-09

  Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

  化合物及其制备和用作治疗剂或预防剂的方法，例如通过靶向八核苷酸焦磷酸酶/磷酸二酯酶-1 (ENPP1)来治疗癌症、细菌或病毒性疾病。
• Discovery and Validation of a Series of Aryl Sulfonamides as Selective Inhibitors of Tissue-Nonspecific Alkaline Phosphatase (TNAP)
  作者：Russell Dahl、Eduard A. Sergienko、Ying Su、Yalda S. Mostofi、Li Yang、Ana Maria Simao、Sonoko Narisawa、Brock Brown、Arianna Mangravita-Novo、Michael Vicchiarelli、Layton H. Smith、W. Charles O’Neill、José Luis Millán、Nicholas D. P. Cosford

  DOI：10.1021/jm900383s

  日期：2009.11.12

  We report the characterization and optimization of drug-like small molecule inhibitors of tissue-nonspecific alkaline phosphatase (TNAP), an enzyme critical for the regulation of extracellular matrix calcification during bone formation and growth. High-throughput screening (HTS) of a small molecule library led to the identification of arylsulfonamides as potent and selective inhibitors of TNAP. Critical structural requirements for activity were determined, and the compounds were subsequently profiled for in vitro activity and bioavailability parameters including metabolic stability and permeability. The plasma levels following subcutaneous administration of a member of the lead series in rat was determined, demonstrating the potential of these TNAP inhibitors as systemically active therapeutic agents to target various diseases involving soft tissue calcification. A representative member of the series was also characterized in mechanistic and kinetic studies.